Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib Effect on Microgynon PK in NSCLC
NCT02751385Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- May 2016
- Primary completion
- Nov 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Ethinylestradiol and Levonorgestrel (0 to last quantifiable data point) and Maximum Measured Concentration of Ethinylestradiol and Levonorgestrel. Started May 2016; status: terminated.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02751385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02751385.